Top.Mail.Ru
    Выбрать город: Минск

    Вы находитесь в городе Ваш город: Минск

    Выбрать другой
    От выбранного города зависят цены и способы оплаты.
    Обратите внимание!
    Уважаемые пациенты! Оказание медицинских услуг несовершеннолетним лицам в возрасте до 14 лет в ИНВИТРО осуществляется в присутствии законного представителя при наличии документов, подтверждающих его полномочия (паспорта родителя и свидетельства о рождении ребенка) или при наличии доверенности от законного представителя. Получить подробную информацию вы можете по телефону единой справочной службы ИНВИТРО: 8(017)222-21-31 , 7807.

    Если у вас повышена температура и есть признаки ОРВИ, рекомендуем вернуться домой и, для получения вами медицинской помощи, обратиться к врачу. Спасибо за понимание!
    ×

    Определение индикаторов Apo 10 и TKTL 1 в крови человека с использованием диагностических наборов «PanTum Detect»

    Описание
    Исследуемый материал Цельная кровь (КЭДТА)
    Метод определения Проточная цитометрия

    Внимание! Требуется предварительная запись. Для записи на исследование обращайтесь по телефонам: 7807 (А1, МТС, Life), +375 (17) 222-21-31.

    Тестирование «PanTum Detect» заключается в изучении макрофагов – подвижных клеток иммунной системы человека, способных поглощать и переваривать чужеродные для организма частицы, в том числе опухолевые клетки. Макрофаги выходят из кровеносного русла, перемещаются в ткани, поглощают специфические опухолевые структуры и мигрируют обратно в периферическую кровь. Опухолевые клетки концентрируются в макрофагах, что позволяет детально исследовать их и точно определить пороговые величины. Пациенты с обоснованным подозрением на злокачественность (получение положительного результата теста «PanTum Detect», выявившего в превышение порогового значения) направляются на дальнейшее обследование с целью подтверждения или исключения диагноза.

    Набор «Pan Tum Detect» предназначен для определения содержания индикаторов Apo 10 и TKTL 1 в макрофагах крови человека методом проточной цитометрии при проведении диагностических и скрининговых исследований онкологических заболеваний. Материалом для проведения исследований служит венозная кровь человека.

     

    Литература

    1. Simon Burg, Blood-Test Based Targeted Visualization Enables Early Detection of Premalignant and Malignant Tumors in Asymptomatic Individuals. J Clin Med Img. 2022; V6(9): 1-12
    2. Coy JF: EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. Int J Mol Sci. 2017 Apr 20;18(4). pii: E878. doi: 10.3390/ijms18040878. Zyagnum Frankfurt, Germany.
    3. Li, B.; Iglesias-Pedraz, J.M.; Chen, L.Y.; Yin, F.; Cadenas, E.; Reddy, S.; Comai, L. Downregulation of the Werner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells. Aging Cell 2014, Apr. 13, 367–378. University of Southern California, Los Angeles, USA / University of Southern California, Los Angeles, USA.
    4. Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A. Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces theWarburg effect in melanoma cells. BMC Cancer. 2016 Feb 22;16:134. Ludwig Institute for Cancer Research, Heidelberg, Australia.
    5. Li, J.; Zhu, S.C.; Li, S.G.; Zhao, Y.; Xu, J.R.; Song, C.Y. TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 2015 Aug;74:71-6. The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
    6. Zerilli M et al: Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer. 2008 Sep 1;113(5):936-44. University of Palermo, Italy.
    7. Ahopelto, K.; Böckelman, C.; Hagström, J.; Koskensalo, S.; Haglund, C. Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer. Cancer Biol. Ther. 2016, 17, 163–168. University of Helsinki and Helsinki University Hospital, Helsinki , Finland.
    8. Bentz S et al: Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion. 2013;88(3):182-92. University Hospital Zurich, Switzerland.Jansen N and Coy JF: Diagnostic use of EDIM-blood test for early detection of colon cancer metastasis. Future Oncol. 2013;9(4):605–9.
    9. Schwaab J et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011;11:363. University Medical Centre Mannheim, Germany.
    10. Diaz-Moralli S et al: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323. Epub 2011 Sep 27. University of Barcelona, Spain.
    11. Xu X et al: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer. 2009 Mar 15;124(6):1330-7. DKFZ German Cancer Research Centre, Heidelberg, Germany.
    12. Langbein S et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006 Feb 27;94(4):578-85. University Hospital Mannheim, Germany.
    13. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
    14. Song, Y.; Liu, D.; He, G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomark. 2015, 15, 591–597. Central South University, Changsha, China.
    15. Yuan W et al: Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010 May;9(9):710-6. Epub 2010 May. Central South University, Changsha, Hunan, China.
    16. Staiger WI et al: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep. 2006 Oct;16(4):657-61. Universitätsmedizin Mannheim. University Hospital Mannheim, Germany.
    17. Rotmann A et al: A new diagnostic approach for the early detection and monitoring of breast cancer patients. Poster Glasgow 9th European Breast Cancer Conference (EBCC-9), 19 to 21 March 2014
    18. Rotmann A et al: A new diagnostic test for monitoring of breast cancer patients. Poster, Deutscher Krebskongress 2014
    19. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 2013, 13:569. Tuebingen University Hospital, DKFZ German Cancer Research Center, Heidelberg, Germany.
    20. Rotmann A: The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients. J. Clin. Oncol., ASCO Meeting Abstracts. 2013; 31:e22006
    21. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59.Central Clinic Bad Berka, Germany.
    22. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012: Poster
    23. Rotmann A et al: Apo10 — a new biomarker for early detection of disorders of cell proliferation and solid tumours. Int J Gynaecol Obstet 119, Supplement 3 (2012), S466. Abstract Figo
    24. Schmidt M et al: Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and downregulation of M2PK. J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25. Epub 2009 Aug 5. University of Wuerzburg, Germany.
    25. Rotmann A et al: TKTL1 — a new biomarker and its relevance in the daily gynaecological practice. Poster FIGO 2009
    26. Foeldi M et al: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007 Apr;17(4):841-5. University Hospital Freiburg, Germany.
    27. Krockenberger M et al: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010 May;30(5):1653-9. University of Wuerzburg, Germany.
    28. Ricciardelli, C.; Lokman, N.A.; Cheruvu, S.; Tan, I.A.; Ween, M.P.; Pyragius, C.E.; Ruszkiewicz, A.; Hoffmann, P.; Oehler, M.K. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin. Exp. Clin Exp Metastasis. 2015 Jun;32(5):441-55. University of Adelaide, Adelaide, Australia
    29. Schmidt M et al: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8. Epub 2008 Apr 3. University of Wuerzburg, Germany.
    30. Krockenberger M et al: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 2007 Jan-Feb;17(1):101-6. University of Wuerzburg, Germany.
    31. Chen H et al: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009 Mar 30;28:43.
    32. Kohrenhagen N et al: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008 Jun;34(3):293-300. University of Wuerzburg, Wuerzburg, Germany.
    33. Wanka C et al: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvationinduced cell death by upregulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10. Goethe University Frankfurt, Germany.
    34. Wani K et al: A prognostic gene expression signature in infratentorial ependymoma. For the Collaborative Ependymoma Research Network. Acta Neuropathol. 2012 May;123(5):727-38. Epub 2012 Feb 10. The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
    35. Völker HU et al: Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol. 2008 Jul;130(1):50-7. University of Wuerzburg, Germany.
    36. Lange CA et al: Enhanced TKTL1 Expression in Malignant Tumors of the Ocular Adnexa Predicts Clinical Outcome. Ophthalmology. 2012 Sep;119(9):1924-9. Epub 2012 Jun 1. University Hospital Freiburg, Germany.
    37. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Zhengzhou University, Zhengzhou, China.
    38. Grimm, M.; Hoefert, S.; Krimmel, M.; Biegner, T.; Feyen, O.; Teriete, P.; Reinert, S. Monitoring carcinogenesis in a case of oral squamous cell carcinoma using a panel of new metabolic blood biomarkers as liquid biopsies. Oral Maxillofac Surg. 2016 Sep;20(3):295-302. Tuebingen University Hospital, Tuebingen, Germany
    39. Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al. A key role for Transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016 Aug 9;7(32):51875-51897. Universitat de Barcelona, Barcelona, Spain
    40. Grimm, M.; Feyen, O.; Coy, J.F.; Hofmann, H.; Teriete, P.; Reinert, S. Analysis of circulating CD14+/CD16+ monocytederived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):301-6. Tuebingen University Hospital, Tuebingen, Germany / Zyagnum AG Frankfurt, Germany
    41. Grimm, M.; Kraut, W.; Hoefert, S.; Krimmel, M.; Biegner, T.; Teriete, P.; Cetindis, M.; Polligkeit, J.; Kluba, S.; Munz, A.; et al. Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomas. Clin. Oral Investig. 2016, 20, 329–338. University Hospital Tuebingen, Germany / Sanford-Burnham Medical Research InstituteLaJollaUSA
    42. Grimm et al: Apoptosis resistance-related ABCB5 and DNaseX (Apo10) expression in oral carcinogenesis. Acta Odontol Scand. 2014 Sep 19:1-7. (Epub ahead of print). Tuebingen University Hospital, Tuebingen, Germany.
    43. Grimm et al.: Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?. J Transl Med. 2014 Jul 21;12:208. Tuebingen University Hospital, Tuebingen, Germany.
    44. Grimm et al: GLUT-1+/TKTL1+ coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):743-53. Tuebingen University Hospital, Tuebingen, Germany.
    45. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013, 13:569. Tuebingen University Hospital, Tuebingen, DKFZ German Cancer Research Center, Heidelberg, Germany.
    46. Grimm M et al: Transketolase-like protein 1 expression in recurrent oral squamous cell carcinoma after curative resection: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul 20. Tuebingen University Hospital, Tuebingen, Germany.
    47. Hartmannsberger D et al: Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. Cancer Lett. 2011 Jan 1;300(1):20-9. Epub 2010 Sep 29. Ludwig-Maximilians-University of Munich, Germany.
    48. Sun W et al: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010 Feb 1;16(3):857-66. Epub 2010 Jan 26
    49. Smith IM et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One. 2009;4(3):e4961. Epub 2009 Mar 23
    50. Völker HU et al: Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6. Epub 2007 Jul 18. University of Wuerzburg, Germany.
    51. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59. Central Clinic Bad Berka, Germany.
    52. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012 Poster
    53. Kayser G et al: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 2011 Dec;43(7):719-24. University Hospital Freiburg, Germany.
    54. Kayser G et al: Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010 Apr 12;5:22. University Hospital Freiburg, Germany.
    55. Prasad V et al: Transketolase-like 1 (TKTL1), a new intracellular marker for staging of non-small cell lung cancer (NSCLC): Correlation with metabolic tumor size on F-18 FDG PET/CT. Poster SNM 2010. Central Clinic Bad Berka, Germany
    56. Xu, I.M.; Lai, R.K.; Lin, S.H.; Tse, A.P.; Chiu, D.K.; Koh, H.Y.; Law, C.T.; Wong, C.M.; Cai, Z.; Wong, C.C.; et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E725-34. The University of Hong Kong, Hong Kong, China.


    Подготовка

    За 2 часа до анализа отказаться от приема пищи, обильного количества жидкостей и курения. Исключить стресс и тяжелые физические нагрузки за 12 часов, а также употребление алкоголя за 24 часа до сдачи анализа.

    Критерии, при которых не рекомендуется сдавать анализ "PanTum Detect»:

    1. ЗАБОЛЕВАНИЯ:

    • Злокачественная опухоль, которая лечилась каким-либо образом (хирургия, лучевая терапия, химиотерапия, гормональная терапия, иммунотерапия и т.д.) - Менее 5 лет после окончания лечения
    • Лейкемия, миелопролиферативная неоплазия (MPN), миелодиспластический синдром (MDS) - Менее 5 лет после окончания лечения
    • Инфекционные заболевания, при которых наблюдался один из симптомов:
      • Озноб
      • Высокая температура (выше 38,5oС)
      • Острый или обострение хронического цистита - Менее 7 дней после полного выздоровления

    2. МЕД. ВМЕШАТЕЛЬСТВА / ТРАВМЫ

    • Опоясывающий лишай (острый, гинекологический, опоясывающий герпес) - Менее 8 недель после полного выздоровления
    • Травма / рана
      Например: перелом кости, глубокий порез (глубже 0,5 см и/или больше 1 см), ссадина (более 5 см в диаметре), открытая рана, ушиб, разрыв связки и т.д. - Менее 8 недель после полного выздоровления
    • Кровь в стуле или в моче - Менее 8 недель после полного выздоровления
    • Язва желудка, эрозивный гастрит (в стадии обострения) - Менее 8 недель после полного выздоровления
    • Грыжа пищеводного отверстия диафрагмы, паховая грыжа (после обнаружения или в стадии обострения) - Менее 8 недель после полного выздоровления
    • Операция - Менее 8 недель после полного выздоровления
    • Медицинские вмешательства
      Например: колоноскопия, гастроскопия, цистоскопия, бронхоскопия, биопсия, лечение зубов при повреждении тканей и т.д. - Менее 8 недель
    • Нанесение татуировок, пирсинг - Менее 8 недель
    • Вакцинация любого вида - Менее 4 недель
    • Контрастное вещество, например для МРТ - Менее 4 недель

    3. МЕДИКАМЕНТЫ

    • Иммунодепрессанты:
      Кортизон в любом виде более 5 мг/день
      После трансплантации
      Иксекизумаб/Тальц - Менее 8 недель после окончания курса лечения
    • Иммуностимуляторы GM-CSF - Менее 8 недель после окончания курса лечения
    • Метотрексат (МТХ) - Менее 8 недель после окончания курса лечения

    4. ПИЩЕВЫЕ ДОБАВКИ

    • Амигдалин (содержится в пищевых добавках из косточек абрикос) - Менее 8 недель после окончания приема


     

    Литература

    1. Simon Burg, Blood-Test Based Targeted Visualization Enables Early Detection of Premalignant and Malignant Tumors in Asymptomatic Individuals. J Clin Med Img. 2022; V6(9): 1-12
    2. Coy JF: EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. Int J Mol Sci. 2017 Apr 20;18(4). pii: E878. doi: 10.3390/ijms18040878. Zyagnum Frankfurt, Germany.
    3. Li, B.; Iglesias-Pedraz, J.M.; Chen, L.Y.; Yin, F.; Cadenas, E.; Reddy, S.; Comai, L. Downregulation of the Werner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells. Aging Cell 2014, Apr. 13, 367–378. University of Southern California, Los Angeles, USA / University of Southern California, Los Angeles, USA.
    4. Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A. Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces theWarburg effect in melanoma cells. BMC Cancer. 2016 Feb 22;16:134. Ludwig Institute for Cancer Research, Heidelberg, Australia.
    5. Li, J.; Zhu, S.C.; Li, S.G.; Zhao, Y.; Xu, J.R.; Song, C.Y. TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 2015 Aug;74:71-6. The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
    6. Zerilli M et al: Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer. 2008 Sep 1;113(5):936-44. University of Palermo, Italy.
    7. Ahopelto, K.; Böckelman, C.; Hagström, J.; Koskensalo, S.; Haglund, C. Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer. Cancer Biol. Ther. 2016, 17, 163–168. University of Helsinki and Helsinki University Hospital, Helsinki , Finland.
    8. Bentz S et al: Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion. 2013;88(3):182-92. University Hospital Zurich, Switzerland.Jansen N and Coy JF: Diagnostic use of EDIM-blood test for early detection of colon cancer metastasis. Future Oncol. 2013;9(4):605–9.
    9. Schwaab J et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011;11:363. University Medical Centre Mannheim, Germany.
    10. Diaz-Moralli S et al: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323. Epub 2011 Sep 27. University of Barcelona, Spain.
    11. Xu X et al: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer. 2009 Mar 15;124(6):1330-7. DKFZ German Cancer Research Centre, Heidelberg, Germany.
    12. Langbein S et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006 Feb 27;94(4):578-85. University Hospital Mannheim, Germany.
    13. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
    14. Song, Y.; Liu, D.; He, G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomark. 2015, 15, 591–597. Central South University, Changsha, China.
    15. Yuan W et al: Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010 May;9(9):710-6. Epub 2010 May. Central South University, Changsha, Hunan, China.
    16. Staiger WI et al: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep. 2006 Oct;16(4):657-61. Universitätsmedizin Mannheim. University Hospital Mannheim, Germany.
    17. Rotmann A et al: A new diagnostic approach for the early detection and monitoring of breast cancer patients. Poster Glasgow 9th European Breast Cancer Conference (EBCC-9), 19 to 21 March 2014
    18. Rotmann A et al: A new diagnostic test for monitoring of breast cancer patients. Poster, Deutscher Krebskongress 2014
    19. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 2013, 13:569. Tuebingen University Hospital, DKFZ German Cancer Research Center, Heidelberg, Germany.
    20. Rotmann A: The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients. J. Clin. Oncol., ASCO Meeting Abstracts. 2013; 31:e22006
    21. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59.Central Clinic Bad Berka, Germany.
    22. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012: Poster
    23. Rotmann A et al: Apo10 — a new biomarker for early detection of disorders of cell proliferation and solid tumours. Int J Gynaecol Obstet 119, Supplement 3 (2012), S466. Abstract Figo
    24. Schmidt M et al: Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and downregulation of M2PK. J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25. Epub 2009 Aug 5. University of Wuerzburg, Germany.
    25. Rotmann A et al: TKTL1 — a new biomarker and its relevance in the daily gynaecological practice. Poster FIGO 2009
    26. Foeldi M et al: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007 Apr;17(4):841-5. University Hospital Freiburg, Germany.
    27. Krockenberger M et al: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010 May;30(5):1653-9. University of Wuerzburg, Germany.
    28. Ricciardelli, C.; Lokman, N.A.; Cheruvu, S.; Tan, I.A.; Ween, M.P.; Pyragius, C.E.; Ruszkiewicz, A.; Hoffmann, P.; Oehler, M.K. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin. Exp. Clin Exp Metastasis. 2015 Jun;32(5):441-55. University of Adelaide, Adelaide, Australia
    29. Schmidt M et al: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8. Epub 2008 Apr 3. University of Wuerzburg, Germany.
    30. Krockenberger M et al: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 2007 Jan-Feb;17(1):101-6. University of Wuerzburg, Germany.
    31. Chen H et al: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009 Mar 30;28:43.
    32. Kohrenhagen N et al: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008 Jun;34(3):293-300. University of Wuerzburg, Wuerzburg, Germany.
    33. Wanka C et al: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvationinduced cell death by upregulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10. Goethe University Frankfurt, Germany.
    34. Wani K et al: A prognostic gene expression signature in infratentorial ependymoma. For the Collaborative Ependymoma Research Network. Acta Neuropathol. 2012 May;123(5):727-38. Epub 2012 Feb 10. The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
    35. Völker HU et al: Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol. 2008 Jul;130(1):50-7. University of Wuerzburg, Germany.
    36. Lange CA et al: Enhanced TKTL1 Expression in Malignant Tumors of the Ocular Adnexa Predicts Clinical Outcome. Ophthalmology. 2012 Sep;119(9):1924-9. Epub 2012 Jun 1. University Hospital Freiburg, Germany.
    37. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Zhengzhou University, Zhengzhou, China.
    38. Grimm, M.; Hoefert, S.; Krimmel, M.; Biegner, T.; Feyen, O.; Teriete, P.; Reinert, S. Monitoring carcinogenesis in a case of oral squamous cell carcinoma using a panel of new metabolic blood biomarkers as liquid biopsies. Oral Maxillofac Surg. 2016 Sep;20(3):295-302. Tuebingen University Hospital, Tuebingen, Germany
    39. Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al. A key role for Transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016 Aug 9;7(32):51875-51897. Universitat de Barcelona, Barcelona, Spain
    40. Grimm, M.; Feyen, O.; Coy, J.F.; Hofmann, H.; Teriete, P.; Reinert, S. Analysis of circulating CD14+/CD16+ monocytederived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):301-6. Tuebingen University Hospital, Tuebingen, Germany / Zyagnum AG Frankfurt, Germany
    41. Grimm, M.; Kraut, W.; Hoefert, S.; Krimmel, M.; Biegner, T.; Teriete, P.; Cetindis, M.; Polligkeit, J.; Kluba, S.; Munz, A.; et al. Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomas. Clin. Oral Investig. 2016, 20, 329–338. University Hospital Tuebingen, Germany / Sanford-Burnham Medical Research InstituteLaJollaUSA
    42. Grimm et al: Apoptosis resistance-related ABCB5 and DNaseX (Apo10) expression in oral carcinogenesis. Acta Odontol Scand. 2014 Sep 19:1-7. (Epub ahead of print). Tuebingen University Hospital, Tuebingen, Germany.
    43. Grimm et al.: Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?. J Transl Med. 2014 Jul 21;12:208. Tuebingen University Hospital, Tuebingen, Germany.
    44. Grimm et al: GLUT-1+/TKTL1+ coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):743-53. Tuebingen University Hospital, Tuebingen, Germany.
    45. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013, 13:569. Tuebingen University Hospital, Tuebingen, DKFZ German Cancer Research Center, Heidelberg, Germany.
    46. Grimm M et al: Transketolase-like protein 1 expression in recurrent oral squamous cell carcinoma after curative resection: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul 20. Tuebingen University Hospital, Tuebingen, Germany.
    47. Hartmannsberger D et al: Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. Cancer Lett. 2011 Jan 1;300(1):20-9. Epub 2010 Sep 29. Ludwig-Maximilians-University of Munich, Germany.
    48. Sun W et al: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010 Feb 1;16(3):857-66. Epub 2010 Jan 26
    49. Smith IM et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One. 2009;4(3):e4961. Epub 2009 Mar 23
    50. Völker HU et al: Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6. Epub 2007 Jul 18. University of Wuerzburg, Germany.
    51. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59. Central Clinic Bad Berka, Germany.
    52. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012 Poster
    53. Kayser G et al: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 2011 Dec;43(7):719-24. University Hospital Freiburg, Germany.
    54. Kayser G et al: Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010 Apr 12;5:22. University Hospital Freiburg, Germany.
    55. Prasad V et al: Transketolase-like 1 (TKTL1), a new intracellular marker for staging of non-small cell lung cancer (NSCLC): Correlation with metabolic tumor size on F-18 FDG PET/CT. Poster SNM 2010. Central Clinic Bad Berka, Germany
    56. Xu, I.M.; Lai, R.K.; Lin, S.H.; Tse, A.P.; Chiu, D.K.; Koh, H.Y.; Law, C.T.; Wong, C.M.; Cai, Z.; Wong, C.C.; et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E725-34. The University of Hong Kong, Hong Kong, China.


    Показания

    Цель проведения анализа «PanTum Detect»

    Обнаружение предраковых или злокачественных опухолей на различных стадиях развития.

     

    Литература

    1. Simon Burg, Blood-Test Based Targeted Visualization Enables Early Detection of Premalignant and Malignant Tumors in Asymptomatic Individuals. J Clin Med Img. 2022; V6(9): 1-12
    2. Coy JF: EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. Int J Mol Sci. 2017 Apr 20;18(4). pii: E878. doi: 10.3390/ijms18040878. Zyagnum Frankfurt, Germany.
    3. Li, B.; Iglesias-Pedraz, J.M.; Chen, L.Y.; Yin, F.; Cadenas, E.; Reddy, S.; Comai, L. Downregulation of the Werner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells. Aging Cell 2014, Apr. 13, 367–378. University of Southern California, Los Angeles, USA / University of Southern California, Los Angeles, USA.
    4. Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A. Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces theWarburg effect in melanoma cells. BMC Cancer. 2016 Feb 22;16:134. Ludwig Institute for Cancer Research, Heidelberg, Australia.
    5. Li, J.; Zhu, S.C.; Li, S.G.; Zhao, Y.; Xu, J.R.; Song, C.Y. TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 2015 Aug;74:71-6. The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
    6. Zerilli M et al: Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer. 2008 Sep 1;113(5):936-44. University of Palermo, Italy.
    7. Ahopelto, K.; Böckelman, C.; Hagström, J.; Koskensalo, S.; Haglund, C. Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer. Cancer Biol. Ther. 2016, 17, 163–168. University of Helsinki and Helsinki University Hospital, Helsinki , Finland.
    8. Bentz S et al: Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion. 2013;88(3):182-92. University Hospital Zurich, Switzerland.Jansen N and Coy JF: Diagnostic use of EDIM-blood test for early detection of colon cancer metastasis. Future Oncol. 2013;9(4):605–9.
    9. Schwaab J et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011;11:363. University Medical Centre Mannheim, Germany.
    10. Diaz-Moralli S et al: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323. Epub 2011 Sep 27. University of Barcelona, Spain.
    11. Xu X et al: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer. 2009 Mar 15;124(6):1330-7. DKFZ German Cancer Research Centre, Heidelberg, Germany.
    12. Langbein S et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006 Feb 27;94(4):578-85. University Hospital Mannheim, Germany.
    13. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
    14. Song, Y.; Liu, D.; He, G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomark. 2015, 15, 591–597. Central South University, Changsha, China.
    15. Yuan W et al: Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010 May;9(9):710-6. Epub 2010 May. Central South University, Changsha, Hunan, China.
    16. Staiger WI et al: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep. 2006 Oct;16(4):657-61. Universitätsmedizin Mannheim. University Hospital Mannheim, Germany.
    17. Rotmann A et al: A new diagnostic approach for the early detection and monitoring of breast cancer patients. Poster Glasgow 9th European Breast Cancer Conference (EBCC-9), 19 to 21 March 2014
    18. Rotmann A et al: A new diagnostic test for monitoring of breast cancer patients. Poster, Deutscher Krebskongress 2014
    19. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 2013, 13:569. Tuebingen University Hospital, DKFZ German Cancer Research Center, Heidelberg, Germany.
    20. Rotmann A: The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients. J. Clin. Oncol., ASCO Meeting Abstracts. 2013; 31:e22006
    21. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59.Central Clinic Bad Berka, Germany.
    22. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012: Poster
    23. Rotmann A et al: Apo10 — a new biomarker for early detection of disorders of cell proliferation and solid tumours. Int J Gynaecol Obstet 119, Supplement 3 (2012), S466. Abstract Figo
    24. Schmidt M et al: Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and downregulation of M2PK. J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25. Epub 2009 Aug 5. University of Wuerzburg, Germany.
    25. Rotmann A et al: TKTL1 — a new biomarker and its relevance in the daily gynaecological practice. Poster FIGO 2009
    26. Foeldi M et al: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007 Apr;17(4):841-5. University Hospital Freiburg, Germany.
    27. Krockenberger M et al: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010 May;30(5):1653-9. University of Wuerzburg, Germany.
    28. Ricciardelli, C.; Lokman, N.A.; Cheruvu, S.; Tan, I.A.; Ween, M.P.; Pyragius, C.E.; Ruszkiewicz, A.; Hoffmann, P.; Oehler, M.K. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin. Exp. Clin Exp Metastasis. 2015 Jun;32(5):441-55. University of Adelaide, Adelaide, Australia
    29. Schmidt M et al: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8. Epub 2008 Apr 3. University of Wuerzburg, Germany.
    30. Krockenberger M et al: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 2007 Jan-Feb;17(1):101-6. University of Wuerzburg, Germany.
    31. Chen H et al: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009 Mar 30;28:43.
    32. Kohrenhagen N et al: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008 Jun;34(3):293-300. University of Wuerzburg, Wuerzburg, Germany.
    33. Wanka C et al: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvationinduced cell death by upregulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10. Goethe University Frankfurt, Germany.
    34. Wani K et al: A prognostic gene expression signature in infratentorial ependymoma. For the Collaborative Ependymoma Research Network. Acta Neuropathol. 2012 May;123(5):727-38. Epub 2012 Feb 10. The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
    35. Völker HU et al: Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol. 2008 Jul;130(1):50-7. University of Wuerzburg, Germany.
    36. Lange CA et al: Enhanced TKTL1 Expression in Malignant Tumors of the Ocular Adnexa Predicts Clinical Outcome. Ophthalmology. 2012 Sep;119(9):1924-9. Epub 2012 Jun 1. University Hospital Freiburg, Germany.
    37. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Zhengzhou University, Zhengzhou, China.
    38. Grimm, M.; Hoefert, S.; Krimmel, M.; Biegner, T.; Feyen, O.; Teriete, P.; Reinert, S. Monitoring carcinogenesis in a case of oral squamous cell carcinoma using a panel of new metabolic blood biomarkers as liquid biopsies. Oral Maxillofac Surg. 2016 Sep;20(3):295-302. Tuebingen University Hospital, Tuebingen, Germany
    39. Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al. A key role for Transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016 Aug 9;7(32):51875-51897. Universitat de Barcelona, Barcelona, Spain
    40. Grimm, M.; Feyen, O.; Coy, J.F.; Hofmann, H.; Teriete, P.; Reinert, S. Analysis of circulating CD14+/CD16+ monocytederived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):301-6. Tuebingen University Hospital, Tuebingen, Germany / Zyagnum AG Frankfurt, Germany
    41. Grimm, M.; Kraut, W.; Hoefert, S.; Krimmel, M.; Biegner, T.; Teriete, P.; Cetindis, M.; Polligkeit, J.; Kluba, S.; Munz, A.; et al. Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomas. Clin. Oral Investig. 2016, 20, 329–338. University Hospital Tuebingen, Germany / Sanford-Burnham Medical Research InstituteLaJollaUSA
    42. Grimm et al: Apoptosis resistance-related ABCB5 and DNaseX (Apo10) expression in oral carcinogenesis. Acta Odontol Scand. 2014 Sep 19:1-7. (Epub ahead of print). Tuebingen University Hospital, Tuebingen, Germany.
    43. Grimm et al.: Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?. J Transl Med. 2014 Jul 21;12:208. Tuebingen University Hospital, Tuebingen, Germany.
    44. Grimm et al: GLUT-1+/TKTL1+ coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):743-53. Tuebingen University Hospital, Tuebingen, Germany.
    45. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013, 13:569. Tuebingen University Hospital, Tuebingen, DKFZ German Cancer Research Center, Heidelberg, Germany.
    46. Grimm M et al: Transketolase-like protein 1 expression in recurrent oral squamous cell carcinoma after curative resection: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul 20. Tuebingen University Hospital, Tuebingen, Germany.
    47. Hartmannsberger D et al: Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. Cancer Lett. 2011 Jan 1;300(1):20-9. Epub 2010 Sep 29. Ludwig-Maximilians-University of Munich, Germany.
    48. Sun W et al: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010 Feb 1;16(3):857-66. Epub 2010 Jan 26
    49. Smith IM et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One. 2009;4(3):e4961. Epub 2009 Mar 23
    50. Völker HU et al: Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6. Epub 2007 Jul 18. University of Wuerzburg, Germany.
    51. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59. Central Clinic Bad Berka, Germany.
    52. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012 Poster
    53. Kayser G et al: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 2011 Dec;43(7):719-24. University Hospital Freiburg, Germany.
    54. Kayser G et al: Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010 Apr 12;5:22. University Hospital Freiburg, Germany.
    55. Prasad V et al: Transketolase-like 1 (TKTL1), a new intracellular marker for staging of non-small cell lung cancer (NSCLC): Correlation with metabolic tumor size on F-18 FDG PET/CT. Poster SNM 2010. Central Clinic Bad Berka, Germany
    56. Xu, I.M.; Lai, R.K.; Lin, S.H.; Tse, A.P.; Chiu, D.K.; Koh, H.Y.; Law, C.T.; Wong, C.M.; Cai, Z.; Wong, C.C.; et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E725-34. The University of Hong Kong, Hong Kong, China.


    Интерпретация результатов

    Интерпретация результатов исследования содержит информацию для лечащего врача и не является диагнозом. Информацию из этого раздела нельзя использовать для самодиагностики и самолечения. Точный диагноз ставит врач, используя как результаты данного обследования, так и нужную информацию из других источников: анамнеза, результатов других обследований и т.д.

    Внимание! За расшифровкой и интерпретацией результатов необходимо обращаться в Учреждение здравоохранения «Витебский областной клинический онкологический диспансер» по номеру телефона +375298704420 с 9-00 до 12-00 ежедневно, за исключением выходных и праздничных дней.

    Формат выдачи.

    Тест количественный. Результат выдается в виде отчета.

    Отрицательный (зеленая зона и отчет):

    Ваш результат PanTum Detect® не дает каких-либо подозрений на существующую потенциально опасную опухоль. Рекомендация к действию: повторить PanTum Detect® через 12 месяцев.

    Пациентам, получившим результата теста PanTum Detect ниже значения 260 p.p.t. и значения APO10 ниже 140 и TKTL1 ниже 120, рекомендуется повторить тест через 1 год ( пациентам моложе 40 лет – 1 раз в два года).

    Серая зона (серая зона и отчет):

    Ваш суммарный результат PanTum Detect® в норме.

    Внимание!!! Один из индикаторов метаболических процессов (APO10 или TKTL1) превышает допустимое значение. Необходимо взять на контроль динамику изменения данного индикатора.

    Рекомендация к действию: повторить PanTum Detect® через 6 месяцев.

    Пациентам, получившим результата теста PanTum Detect в диапазоне от 254 до 259 p.p.t. и показателях значений APO более 140 p.p.t. или TKTL1 более 120 p.p.t., рекомендация повторить анализ через 6 месяцев.

    Положительный (желтая зона и отчет):

    Ваш результат PanTum Detect® превышает пороговое значение.

    Ваш результат PanTum Detect® свидетельствует о ВОЗМОЖНОМ нарушении клеточного метаболизма.

    Рекомендация: провести детальную диагностику вместе с врачом-онкологом, сопровождающим программу. Просим Вас связаться с сотрудниками программы «PanTum Detect» в течении 30 календарных дней для согласования даты и места прохождения детальной диагностики в специализированном государственном лечебном учреждении Республики Беларусь.

    Превышение порогового значения 260 p.p.t. (260 положительных сигналов клеток на 1000 клеток) показывает нарушение клеточного метаболизма, который свидетельствует о возможных развивающихся или существующих опухолях. Интерпретация: при превышении порогового значения пациент направляется на детальную диагностику к врачу-онкологу, сопровождающему программу «PanTum Detect», для подтверждения или исключения диагноза (определение локализации опухоли).

    Тест отклонен (синий отчет):

    Ваш результат PanTum Detect® не может быть интерпретирован корректно из-за индивидуальных особенностей Вашего организма в данный момент.

    Рекомендация к действию: повторить PanTum Detect® через 2 месяца без взимания дополнительных платежей.

    Интерпретация: результат не может быть корректно проанализирован из-за индивидуальных особенностей Вашего организма в данный момент.

    Здесь также возможны следующие причины:

    • Пациент находится в группе с критериями исключения
    • Нарушена технология взятия, хранения или транспортировки биоматериала.

     

    Литература

    1. Simon Burg, Blood-Test Based Targeted Visualization Enables Early Detection of Premalignant and Malignant Tumors in Asymptomatic Individuals. J Clin Med Img. 2022; V6(9): 1-12
    2. Coy JF: EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer. Int J Mol Sci. 2017 Apr 20;18(4). pii: E878. doi: 10.3390/ijms18040878. Zyagnum Frankfurt, Germany.
    3. Li, B.; Iglesias-Pedraz, J.M.; Chen, L.Y.; Yin, F.; Cadenas, E.; Reddy, S.; Comai, L. Downregulation of the Werner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells. Aging Cell 2014, Apr. 13, 367–378. University of Southern California, Los Angeles, USA / University of Southern California, Los Angeles, USA.
    4. Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A. Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces theWarburg effect in melanoma cells. BMC Cancer. 2016 Feb 22;16:134. Ludwig Institute for Cancer Research, Heidelberg, Australia.
    5. Li, J.; Zhu, S.C.; Li, S.G.; Zhao, Y.; Xu, J.R.; Song, C.Y. TKTL1 promotes cell proliferation and metastasis in esophageal squamous cell carcinoma. Biomed Pharmacother. 2015 Aug;74:71-6. The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
    6. Zerilli M et al: Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases. Cancer. 2008 Sep 1;113(5):936-44. University of Palermo, Italy.
    7. Ahopelto, K.; Böckelman, C.; Hagström, J.; Koskensalo, S.; Haglund, C. Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer. Cancer Biol. Ther. 2016, 17, 163–168. University of Helsinki and Helsinki University Hospital, Helsinki , Finland.
    8. Bentz S et al: Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion. 2013;88(3):182-92. University Hospital Zurich, Switzerland.Jansen N and Coy JF: Diagnostic use of EDIM-blood test for early detection of colon cancer metastasis. Future Oncol. 2013;9(4):605–9.
    9. Schwaab J et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 2011;11:363. University Medical Centre Mannheim, Germany.
    10. Diaz-Moralli S et al: Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6(9):e25323. Epub 2011 Sep 27. University of Barcelona, Spain.
    11. Xu X et al: Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer. 2009 Mar 15;124(6):1330-7. DKFZ German Cancer Research Centre, Heidelberg, Germany.
    12. Langbein S et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer. 2006 Feb 27;94(4):578-85. University Hospital Mannheim, Germany.
    13. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
    14. Song, Y.; Liu, D.; He, G. TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients. Cancer Biomark. 2015, 15, 591–597. Central South University, Changsha, China.
    15. Yuan W et al: Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther. 2010 May;9(9):710-6. Epub 2010 May. Central South University, Changsha, Hunan, China.
    16. Staiger WI et al: Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep. 2006 Oct;16(4):657-61. Universitätsmedizin Mannheim. University Hospital Mannheim, Germany.
    17. Rotmann A et al: A new diagnostic approach for the early detection and monitoring of breast cancer patients. Poster Glasgow 9th European Breast Cancer Conference (EBCC-9), 19 to 21 March 2014
    18. Rotmann A et al: A new diagnostic test for monitoring of breast cancer patients. Poster, Deutscher Krebskongress 2014
    19. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 2013, 13:569. Tuebingen University Hospital, DKFZ German Cancer Research Center, Heidelberg, Germany.
    20. Rotmann A: The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients. J. Clin. Oncol., ASCO Meeting Abstracts. 2013; 31:e22006
    21. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59.Central Clinic Bad Berka, Germany.
    22. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012: Poster
    23. Rotmann A et al: Apo10 — a new biomarker for early detection of disorders of cell proliferation and solid tumours. Int J Gynaecol Obstet 119, Supplement 3 (2012), S466. Abstract Figo
    24. Schmidt M et al: Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and downregulation of M2PK. J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25. Epub 2009 Aug 5. University of Wuerzburg, Germany.
    25. Rotmann A et al: TKTL1 — a new biomarker and its relevance in the daily gynaecological practice. Poster FIGO 2009
    26. Foeldi M et al: Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007 Apr;17(4):841-5. University Hospital Freiburg, Germany.
    27. Krockenberger M et al: Expression of transketolase-like 1 protein (TKTL1) in human endometrial cancer. Anticancer Res. 2010 May;30(5):1653-9. University of Wuerzburg, Germany.
    28. Ricciardelli, C.; Lokman, N.A.; Cheruvu, S.; Tan, I.A.; Ween, M.P.; Pyragius, C.E.; Ruszkiewicz, A.; Hoffmann, P.; Oehler, M.K. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin. Exp. Clin Exp Metastasis. 2015 Jun;32(5):441-55. University of Adelaide, Adelaide, Australia
    29. Schmidt M et al: Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008 Jul;139(1):72-8. Epub 2008 Apr 3. University of Wuerzburg, Germany.
    30. Krockenberger M et al: Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 2007 Jan-Feb;17(1):101-6. University of Wuerzburg, Germany.
    31. Chen H et al: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res. 2009 Mar 30;28:43.
    32. Kohrenhagen N et al: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res. 2008 Jun;34(3):293-300. University of Wuerzburg, Wuerzburg, Germany.
    33. Wanka C et al: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvationinduced cell death by upregulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10. Goethe University Frankfurt, Germany.
    34. Wani K et al: A prognostic gene expression signature in infratentorial ependymoma. For the Collaborative Ependymoma Research Network. Acta Neuropathol. 2012 May;123(5):727-38. Epub 2012 Feb 10. The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
    35. Völker HU et al: Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol. 2008 Jul;130(1):50-7. University of Wuerzburg, Germany.
    36. Lange CA et al: Enhanced TKTL1 Expression in Malignant Tumors of the Ocular Adnexa Predicts Clinical Outcome. Ophthalmology. 2012 Sep;119(9):1924-9. Epub 2012 Jun 1. University Hospital Freiburg, Germany.
    37. Dong, Y.; Wang, M. Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. Biomed. Pharmacother. 2017, 85, 672– 678. Zhengzhou University, Zhengzhou, China.
    38. Grimm, M.; Hoefert, S.; Krimmel, M.; Biegner, T.; Feyen, O.; Teriete, P.; Reinert, S. Monitoring carcinogenesis in a case of oral squamous cell carcinoma using a panel of new metabolic blood biomarkers as liquid biopsies. Oral Maxillofac Surg. 2016 Sep;20(3):295-302. Tuebingen University Hospital, Tuebingen, Germany
    39. Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al. A key role for Transketolase-like 1 in tumor metabolic reprogramming. Oncotarget. 2016 Aug 9;7(32):51875-51897. Universitat de Barcelona, Barcelona, Spain
    40. Grimm, M.; Feyen, O.; Coy, J.F.; Hofmann, H.; Teriete, P.; Reinert, S. Analysis of circulating CD14+/CD16+ monocytederived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Mar;121(3):301-6. Tuebingen University Hospital, Tuebingen, Germany / Zyagnum AG Frankfurt, Germany
    41. Grimm, M.; Kraut, W.; Hoefert, S.; Krimmel, M.; Biegner, T.; Teriete, P.; Cetindis, M.; Polligkeit, J.; Kluba, S.; Munz, A.; et al. Evaluation of a biomarker based blood test for monitoring surgical resection of oral squamous cell carcinomas. Clin. Oral Investig. 2016, 20, 329–338. University Hospital Tuebingen, Germany / Sanford-Burnham Medical Research InstituteLaJollaUSA
    42. Grimm et al: Apoptosis resistance-related ABCB5 and DNaseX (Apo10) expression in oral carcinogenesis. Acta Odontol Scand. 2014 Sep 19:1-7. (Epub ahead of print). Tuebingen University Hospital, Tuebingen, Germany.
    43. Grimm et al.: Association of cancer metabolism-related proteins with oral carcinogenesis – indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?. J Transl Med. 2014 Jul 21;12:208. Tuebingen University Hospital, Tuebingen, Germany.
    44. Grimm et al: GLUT-1+/TKTL1+ coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):743-53. Tuebingen University Hospital, Tuebingen, Germany.
    45. Grimm M et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013, 13:569. Tuebingen University Hospital, Tuebingen, DKFZ German Cancer Research Center, Heidelberg, Germany.
    46. Grimm M et al: Transketolase-like protein 1 expression in recurrent oral squamous cell carcinoma after curative resection: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jul 20. Tuebingen University Hospital, Tuebingen, Germany.
    47. Hartmannsberger D et al: Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. Cancer Lett. 2011 Jan 1;300(1):20-9. Epub 2010 Sep 29. Ludwig-Maximilians-University of Munich, Germany.
    48. Sun W et al: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010 Feb 1;16(3):857-66. Epub 2010 Jan 26
    49. Smith IM et al: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One. 2009;4(3):e4961. Epub 2009 Mar 23
    50. Völker HU et al: Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2007 Dec;264(12):1431-6. Epub 2007 Jul 18. University of Wuerzburg, Germany.
    51. Feyen O et al: EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349-59. Central Clinic Bad Berka, Germany.
    52. Feyen O et al: EDIM blood test: a non-invasive method to detect patients with malignancies. Cell Symposia July 6-8, 2012 Poster
    53. Kayser G et al: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology. 2011 Dec;43(7):719-24. University Hospital Freiburg, Germany.
    54. Kayser G et al: Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol. 2010 Apr 12;5:22. University Hospital Freiburg, Germany.
    55. Prasad V et al: Transketolase-like 1 (TKTL1), a new intracellular marker for staging of non-small cell lung cancer (NSCLC): Correlation with metabolic tumor size on F-18 FDG PET/CT. Poster SNM 2010. Central Clinic Bad Berka, Germany
    56. Xu, I.M.; Lai, R.K.; Lin, S.H.; Tse, A.P.; Chiu, D.K.; Koh, H.Y.; Law, C.T.; Wong, C.M.; Cai, Z.; Wong, C.C.; et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):E725-34. The University of Hong Kong, Hong Kong, China.


    Артикул: 2014
    Цена:360 руб. 83 коп.
    В цену исследования не входит стоимость расходных материалов и услуга по взятию биоматериала

    *Обращаем Ваше внимание на то, что при заказе нескольких исследований, на одном бланке могут быть отражены несколько результатов исследований.

    Сдать анализ "Определение индикаторов Apo 10 и TKTL 1 в крови человека с использованием диагностических наборов «PanTum Detect»" вы можете в Минске и других городах Республики Беларусь. Обратите внимание, что цена анализа, стоимость процедуры взятия биоматериала, методы и сроки выполнения исследований в региональных медицинских офисах могут отличаться
    Наверх